Core Insights - Herantis Pharma has been selected to lead a consortium for a EUR 8.0 million grant from the Horizon Europe 2025 Research and Innovation program to support a Phase 2 proof-of-concept trial of HER-096 in Parkinson's disease [1][2][3] Funding and Study Details - The funding will facilitate a Phase 2, double-blind, placebo-controlled, randomized efficacy and safety study of HER-096 in early-stage Parkinson's disease patients [2] - The study will commence once necessary preparations, including regulatory approvals, are completed [2] Company Background and Product Information - Herantis Pharma is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Parkinson's disease, with HER-096 as its lead product [7][8] - HER-096 is a first-in-class small peptide designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF) and is administered subcutaneously [7][9] - Previous clinical trials have shown HER-096 to be generally safe and well-tolerated, with promising preclinical results indicating its potential to stop disease progression and improve patient quality of life [11][10] Horizon Europe Initiative - The Horizon Europe initiative aims to accelerate the translation of biotech research into clinical development, focusing on faster access to innovative therapies, increasing clinical trials in the EU, and enhancing the competitiveness of SMEs in the health biotech sector [6]

LOS ANGELES, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises UniQure N.V., (“uniQure” or the "Company") (NASDAQ: QURE) investors of a class action on behalf of investors that bought securities between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). uniQure investors have until April 13, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal righ ...

In its upcoming report, BioMarin Pharmaceutical (BMRN) is predicted by Wall Street analysts to post quarterly earnings of $0.25 per share, reflecting a decline of 72.8% compared to the same period last year. Revenues are forecasted to be $829.66 million, representing a year-over-year increase of 11%.Over the last 30 days, there has been a downward revision of 2.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of ...

The Gross Law Firm Notifies REGENXBIO Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RGNX [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX).Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Vistagen between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Faruqi & Far ...

Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as a leading immunotherapy stock by hedge funds, reporting strong fiscal Q4 and full year 2025 results, driven by the growth of Biktarvy, Descovy, and the launch of Yeztugo, the first twice-yearly HIV prevention therapy in the country [1] Financial Performance - Total fiscal Q4 revenues increased by 5% to $7.9 billion compared to the previous year, primarily due to higher sales of HIV and Liver Disease products, although this was partially offset by lower sales of Veklury® [2] Analyst Ratings - Following the earnings release, several analysts updated their ratings for Gilead. Needham raised the price target to $170 from $140 while maintaining a Buy rating, and Scotiabank increased its target to $177 from $140, keeping an Outperform rating [3] - BofA also raised its price target to $162 from $154, maintaining a Buy rating, and expressed confidence in the company's growth for 2026 based on strong fiscal Q4 performance [4] Company Overview - Gilead Sciences, Inc. is a biotech company focused on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19, with a portfolio that addresses unmet medical needs [5]

Core Insights - Amgen Inc. (NASDAQ:AMGN) is recognized as a strong immunotherapy stock by hedge funds, but has recently been downgraded to Hold from Buy by Freedom Capital, with a revised price target of $375 from $360, citing fair value and ongoing exclusivity challenges [1][2]. Financial Performance - For fiscal Q4, Amgen reported total revenues of $9.9 billion, reflecting a 9% increase year-over-year, with product sales growing by 7% driven by a 10% increase in volume [3]. - The full-year revenue for 2025 reached $36.8 billion, marking a 10% increase compared to the previous year [3]. Product Developments - The European Commission approved UPLIZNA® as an add-on treatment for adults with generalized myasthenia gravis, providing a new targeted treatment option that may enhance long-term disease control [2].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Far ...

We recently published 10 Losing Stocks in an Otherwise Optimistic Market. Halozyme Therapeutics Inc. (NASDAQ:HALO) was one of the worst performers on Wednesday. Halozyme snapped a two-day winning streak on Wednesday, shedding 9.01 percent to finish at $73.23 as investors digested a weak earnings performance in both the fourth quarter and full-year 2025. In an updated report, Halozyme Therapeutics Inc. (NASDAQ:HALO) said that net income last year fell by 28.6 percent to $317 million from $444 million in 2 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Faruqi ...